Nektar Therapeutics [NASDAQ: NKTR] traded at a low on Wednesday, posting a -4.67 loss after which it closed the day’ session at $1.02.
The results of the trading session contributed to over 6094864 shares changing hands. Over the past one week, the price volatility of Nektar Therapeutics stands at 6.84% while the volatility over the past one month is 7.05%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for NKTR stock reached $188.15 million, with 184.46 million shares outstanding and 178.21 million shares in the current float. Compared to the average trading volume of 1.45M shares, NKTR reached a trading volume of 6094864 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Nektar Therapeutics [NKTR]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NKTR shares is $3.58 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NKTR stock is a recommendation set at 2.71. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for Nektar Therapeutics shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on November 04, 2024. While these analysts kept the previous recommendation, BTIG Research raised their target price to Buy. The new note on the price target was released on September 30, 2024, representing the official price target for Nektar Therapeutics stock. Previously, the target price had yet another raise to $2, while Rodman & Renshaw analysts kept a Buy rating on NKTR stock.
The Average True Range (ATR) for Nektar Therapeutics is set at 0.08, with the Price to Sales ratio for NKTR stock in the period of the last 12 months amounting to 2.02. The Price to Book ratio for the last quarter was 3.85, with the Price to Cash per share for the same quarter was set at 1.33.
How has NKTR stock performed recently?
Nektar Therapeutics [NKTR] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.67. With this latest performance, NKTR shares dropped by -23.31% in over the last four-week period, additionally sinking by -28.17% over the last 6 months – not to mention a rise of 98.06% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NKTR stock in for the last two-week period is set at 37.65, with the RSI for the last a single of trading hit 35.40, and the three-weeks RSI is set at 39.79 for Nektar Therapeutics [NKTR]. The present Moving Average for the last 50 days of trading for this stock 1.2498, while it was recorded at 1.1080 for the last single week of trading, and 1.2506 for the last 200 days.
Nektar Therapeutics [NKTR]: Deeper insight into the fundamentals
Nektar Therapeutics’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.24 and a Current Ratio set at 4.24.
Earnings analysis for Nektar Therapeutics [NKTR]
With the latest financial reports released by the company, Nektar Therapeutics posted -0.22/share EPS, while the average EPS was predicted by analysts to be reported at -0.2/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.02. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NKTR. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Nektar Therapeutics go to -7.30%.
Insider trade positions for Nektar Therapeutics [NKTR]
There are presently around $76.66%, or 77.46%% of NKTR stock, in the hands of institutional investors. The top three institutional holders of NKTR stocks are: DEEP TRACK CAPITAL, LP with ownership of 17.88 million shares, which is approximately 9.1789%. BLACKROCK INC., holding 15.16 million shares of the stock with an approximate value of $$18.79 million in NKTR stocks shares; and BLACKROCK INC., currently with $$16.08 million in NKTR stock with ownership which is approximately 6.6587%.
